Press Releases

Mulvihill Canadian Bank Enhanced Yield ETF Declares Monthly Distribution May 3, 2024 04:01PM

TORONTO, May 03, 2024 (GLOBE NEWSWIRE) -- (TSX: CBNK) Mulvihill Canadian Bank Enhanced Yield ETF has declared a monthly cash distribution in the amount of $0.058333 per unit, payable on June 7, 2024 to unitholders of record on May 31, 2024.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at [email protected] or visit www.mulvihill.com.

John Germain, Senior Vice-President & CFOMulvihill Capital... (continue reading...)

S Split Corp. Declares Monthly Distribution May 3, 2024 04:01PM

TORONTO, May 03, 2024 (GLOBE NEWSWIRE) -- (TSX: SBN; SBN.PR.A) S Split Corp. has declared monthly distributions, payable on May 31, 2024 to shareholders of record on May 15, 2024. Due to the decline in the net asset value (“NAV”) per unit below $16.50, the Company has suspended distributions on its Class A Shares in accordance with the Articles of Incorporation. The NAV per Unit on April 30, 2024 was $12.03.

Share ClassTicker    Amount Per ShareClass A... (continue reading...)

Mulvihill U.S. Health Care Enhanced Yield ETF Declares Monthly Distribution May 3, 2024 04:01PM

TORONTO, May 03, 2024 (GLOBE NEWSWIRE) -- (TSX: XLVE) Mulvihill U.S. Health Care Enhanced Yield ETF has declared a monthly cash distribution in the amount of $0.058333 per unit, payable on June 7, 2024 to unitholders of record on May 31, 2024.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at [email protected] or visit www.mulvihill.com.

John Germain, Senior VP & CFOMulvihill Capital Management... (continue reading...)

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 3, 2024 04:01PM

BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance... (continue reading...)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 3, 2024 04:01PM

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 31,750 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 47,625 shares of Vor Bio’s common stock to six newly... (continue reading...)